Last reviewed · How we verify
SQ SLIT-tablet
At a glance
| Generic name | SQ SLIT-tablet |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- COVID-19
- Influenza
- Pharyngitis
- Throat irritation
- Oral pruritus
- Paraesthesia oral
- Tongue pruritus
Key clinical trials
- A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 (PHASE3)
- Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction (PHASE2)
- A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis (PHASE3)
- Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT (PHASE2, PHASE3)
- Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
- Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
- A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber (PHASE3)
- Long-Term Effects of Sublingual Grass Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SQ SLIT-tablet CI brief — competitive landscape report
- SQ SLIT-tablet updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI